Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

CARACO Data Add to Evidence Supporting Omission of Lymphadenectomy in Advanced Ovarian Cancer Without Suspicious Lymph Nodes

August 27th 2024

Jean-Marc Classe, MD, PhD, discusses omitting lymphadenectomy in patients with advanced epithelial ovarian cancer.

PARP Inhibitors and ADCs Spark Change Across Ovarian and Cervical Cancer Paradigms

August 26th 2024

Ritu Salani, MD, discusses the role of ADCs in ovarian cancer and what the future of the post-IO setting in cervical cancer management may look like.

Dr Chambers on the Role of Genetic Testing and PARP Inhibitors in Ovarian Cancer

August 23rd 2024

Laura J. Chambers, DO, discusses the role of genetic testing and PARP inhibitor maintenance therapy for patients with ovarian cancer.

Suvemcitug Plus Chemo Boost PFS in Platinum-Resistant Ovarian Cancer

August 4th 2024

Suvemcitug plus chemotherapy improved progression-free survival in platinum-resistant ovarian cancer.

Ceralasertib/Olaparib is Active in Recurrent, Platinum-Sensitive, Recurrent Ovarian Cancer Irrespective of HRD Status

August 3rd 2024

Ceralasertib plus olaparib demonstrated clinical activity in platinum-sensitive, recurrent, high-grade serous ovarian cancer, regardless of HRD status.

IMNN-01 Plus Perioperative Chemo Improves OS in Newly Diagnosed, Advanced Ovarian Cancer

July 30th 2024

IMNN-001 plus perioperative chemotherapy improved overall survival in newly diagnosed, advanced ovarian cancer.

Rezatapopt Takes Aim at Previously Untargetable p53 Allele to Treat Advanced Solid Tumors

July 19th 2024

Rezatapopt has displayed early signals of efficacy and tolerability in p53 Y220C-mutated solid tumors.

Nivolumab/Ipilimumab Yields Responses in Ovarian Clear Cell Carcinoma

July 10th 2024

Don Dizon, MD, discusses updated findings from the BrUOG 354 trial and the future of immunotherapy for patients with ovarian cancers.

OncLive’s June Roundup of Key FDA Approvals in Oncology

July 3rd 2024

Here is your guide to the important regulatory decisions made by the FDA in June 2024.

FDA Grants Fast Track Designation to Radspherin for Peritoneal Carcinomatosis From Ovarian Cancer

July 3rd 2024

The FDA has granted fast track designation to Radspherin for the treatment of patients with peritoneal metastases from ovarian cancer.

Dr Mujumdar on Key Trials Evaluating Treatments for Ovarian Cancer

July 2nd 2024

Vaidehi Mujumdar, MD, discusses several key trials that have helped shift the ovarian cancer treatment paradigm.

FDA Approves Tepylute for Breast and Ovarian Cancer Treatment

June 28th 2024

The FDA has approved a new drug application for Tepylute, a ready-to-dilute formulation to treat breast and ovarian cancers.

Mirvetuximab Soravtansine Elicits Benefits in Ovarian Cancer Regardless of Dose Modifications

June 21st 2024

Mirvetuximab soravtansine generated PFS, OS, and ORR improvements in patients with ovarian cancer who required dose modifications in the MIRASOL trial.

Durvalumab Combo Before Olaparib-Based Maintenance Sustains PFS Benefit in BRCA-Unmutated Ovarian Cancer

June 20th 2024

Durvalumab/chemotherapy/bevacizumab, then durvalumab/bevacizumab/olaparib maintenance, sustained a PFS benefit in BRCA-unmutated advanced ovarian cancer.

FDA Places Partial Clinical Holds on 3 Trials Evaluating Azenosertib in Advanced Solid Tumors

June 19th 2024

The FDA placed partial clinical holds on trials evaluating azenosertib in advanced solid tumors, including ovarian cancer and uterine serous carcinoma.

Cannavale on Pre-Existing Comorbidities and Remission Rates in Epithelial Ovarian Cancer

June 13th 2024

Kimberly Cannavale, MPH, discusses findings from a retrospective study of comorbidity and remission outcomes in epithelial ovarian cancer.

Mirvetuximab Soravtansine Meets Primary End Point of PICCOLO Trial in FRα-High, Platinum-Sensitive Ovarian Cancer

June 6th 2024

Mirvetuximab soravtansine led to an ORR of 51.9% in heavily pretreated patients with FRα-positive, platinum-sensitive ovarian cancer.

Dr Classe on Lymphadenectomy Omission in Advanced Epithelial Ovarian Cancer

June 4th 2024

Jean-Marc Classe, MD, PhD, discusses lymphadenectomy omission following cytoreductive surgery after chemotherapy in advanced epithelial ovarian cancer.

Addition of Atezolizumab to Chemotherapy and Bevacizumab Does Not Yield Benefit in Ovarian Cancer

June 2nd 2024

The addition of atezolizumab to bevacizumab and chemotherapy did not significantly improve overall survival or progression-free survival in patients with recurrent ovarian cancer.

Nivolumab/Ipilimumab Bests Nivolumab in Ovarian and Extra-Renal Clear Cell Carcinomas

June 2nd 2024

The combination of nivolumab and ipilimumab improved responses as well as survival outcomes in patients with ovarian or gynecologic clear cell carcinomas.